Tumor-infiltration of T-lymphocytes is Inversely Correlated with Clinicopathologic Factors in Endometrial Adenocarcinoma

Overview

Journal Obstet Gynecol Sci

Specialty Gynecology & Obstetrics

Date 2014 Aug 9

PMID 25105099

Citations 9

Authors

In Kook Jung

Sun Sook Kim

Dong Soo Suh

Ki Hyung Kim

Chang Hoon Lee

Man Soo Yoon

Affiliations

Soon will be listed here.

Abstract

Objective: The aim of this study was to determine the distribution of T-lymphocytes and their relationship with clinicopathologic factors in endometrial carcinoma.

Methods: Samples were collected from 89 patients with endometrial endometrioid adenocarcinoma treated in Pusan National University Hospital from 2004 to 2011. Normal endometrial tissues were obtained from 30 hysterectomized women with benign adnexal masses and served as controls. Paraffin-embedded sections were immunohistochemically stained for CD8 (cytotoxic) and CD4 (helper) T-lymphocytes. The relationship of these cells with stage, histological grade, myometrial invasion, and lymph node metastasis was analyzed.

Results: The proportion of CD8+ and CD4+ lymphocytes in the endometrial endometrioid adenocarcinoma tissues was 67.4% (60/89) and 44.9% (40/89), respectively, which was significantly higher (P<0.05) than in the control group. The extent of CD8+ lymphocyte expression was negatively correlated with histologic grade, myometrial invasion, and lymph node metastasis. The proportion of infiltration of the CD4+ lymphocytes was negatively correlated with histologic grade and myometrial invasion.

Conclusion: The high rate of infiltration of T-lymphocytes was negatively correlated with histologic grade, myometrial invasion, and lymph node metastasis. Our findings suggest that tumor-infiltrating T-lymphocytes may be used as pathologic prognostic factors in endometrial carcinoma.

Citing Articles

Clinical Correlations between Serological Markers and Endometrial Cancer.

Marin A, Filipescu A, Petca R, Vladareanu R, Petca A Cancers (Basel). 2024; 16(10).

PMID: 38792013 PMC: 11120108. DOI: 10.3390/cancers16101935.

Exploring prognostic microbiota markers in patients with endometrial carcinoma: Intratumoral insights.

Liu J, Qu Y, Li Y, Xu Y, Yan Y, Qin H Heliyon. 2024; 10(6):e27879.

PMID: 38515713 PMC: 10955307. DOI: 10.1016/j.heliyon.2024.e27879.

Prognostic implications of tumor-infiltrating T cells in early-stage endometrial cancer.

Mendiola M, Pellinen T, Ramon-Patino J, Berjon A, Bruck O, Heredia-Soto V Mod Pathol. 2021; 35(2):256-265.

PMID: 34642425 DOI: 10.1038/s41379-021-00930-7.

Endometrial Cancer Suppresses CD8+ T Cell-Mediated Cytotoxicity in Postmenopausal Women.

Patel M, Shen Z, Rodriguez-Garcia M, Usherwood E, Tafe L, Wira C Front Immunol. 2021; 12:657326.

PMID: 33968059 PMC: 8103817. DOI: 10.3389/fimmu.2021.657326.

Preoperative Circulating Lymphocyte and Monocyte Counts Correlate with Patient Outcomes in Type I and Type II Endometrial Cancer.

Burgess B, Levine B, Taylor R, Kelly M Reprod Sci. 2020; 27(1):194-203.

PMID: 32046381 PMC: 11758426. DOI: 10.1007/s43032-019-00009-4.

References

Kobayashi N, Hiraoka N, Yamagami W, Ojima H, Kanai Y, Kosuge T . FOXP3+ regulatory T cells affect the development and progression of hepatocarcinogenesis. Clin Cancer Res. 2007; 13(3):902-11. DOI: 10.1158/1078-0432.CCR-06-2363. View

de Jong R, Leffers N, Boezen H, ten Hoor K, van der Zee A, Hollema H . Presence of tumor-infiltrating lymphocytes is an independent prognostic factor in type I and II endometrial cancer. Gynecol Oncol. 2009; 114(1):105-10. DOI: 10.1016/j.ygyno.2009.03.022. View

Clark Jr W, Elder D, Guerry 4th D, Braitman L, Trock B, Schultz D . Model predicting survival in stage I melanoma based on tumor progression. J Natl Cancer Inst. 1989; 81(24):1893-904. DOI: 10.1093/jnci/81.24.1893. View

Wallace A, Gibson D, Saunders P, Jabbour H . Inflammatory events in endometrial adenocarcinoma. J Endocrinol. 2010; 206(2):141-57. DOI: 10.1677/JOE-10-0072. View

Arafa M, Boniver J, Delvenne P . Progression model tissue microarray (TMA) for the study of uterine carcinomas. Dis Markers. 2010; 28(5):267-72. PMC: 3833607. DOI: 10.3233/DMA-2010-0709. View

van der Horst P, Wang Y, Vandenput I, Kuhne L, Ewing P, van IJcken W . Progesterone inhibits epithelial-to-mesenchymal transition in endometrial cancer. PLoS One. 2012; 7(1):e30840. PMC: 3266274. DOI: 10.1371/journal.pone.0030840. View

Schumacher K, Haensch W, Roefzaad C, Schlag P . Prognostic significance of activated CD8(+) T cell infiltrations within esophageal carcinomas. Cancer Res. 2001; 61(10):3932-6. View

Jackaman C, Bundell C, Kinnear B, Smith A, Filion P, van Hagen D . IL-2 intratumoral immunotherapy enhances CD8+ T cells that mediate destruction of tumor cells and tumor-associated vasculature: a novel mechanism for IL-2. J Immunol. 2003; 171(10):5051-63. DOI: 10.4049/jimmunol.171.10.5051. View

Naito Y, Saito K, Shiiba K, Ohuchi A, Saigenji K, Nagura H . CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res. 1998; 58(16):3491-4. View

10.

Ferguson A, Moore M, Fox H . Expression of MHC products and leucocyte differentiation antigens in gynaecological neoplasms: an immunohistological analysis of the tumour cells and infiltrating leucocytes. Br J Cancer. 1985; 52(4):551-63. PMC: 1977246. DOI: 10.1038/bjc.1985.227. View

11.

Ohno Y, Ohno S, Suzuki N, Kamei T, Inagawa H, Soma G . Role of cyclooxygenase-2 in immunomodulation and prognosis of endometrial carcinoma. Int J Cancer. 2004; 114(5):696-701. DOI: 10.1002/ijc.20777. View

12.

Clark C, Hingorani S, Mick R, Combs C, Tuveson D, Vonderheide R . Dynamics of the immune reaction to pancreatic cancer from inception to invasion. Cancer Res. 2007; 67(19):9518-27. DOI: 10.1158/0008-5472.CAN-07-0175. View

13.

Zhang L, Conejo-Garcia J, Katsaros D, Gimotty P, Massobrio M, Regnani G . Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med. 2003; 348(3):203-13. DOI: 10.1056/NEJMoa020177. View

14.

Bontkes H, de Gruijl T, Walboomers J, van den Muysenberg A, Gunther A, Scheper R . Assessment of cytotoxic T-lymphocyte phenotype using the specific markers granzyme B and TIA-1 in cervical neoplastic lesions. Br J Cancer. 1997; 76(10):1353-60. PMC: 2228142. DOI: 10.1038/bjc.1997.560. View

15.

Yakirevich E, Izhak O, Rennert G, Kovacs Z, Resnick M . Cytotoxic phenotype of tumor infiltrating lymphocytes in medullary carcinoma of the breast. Mod Pathol. 1999; 12(11):1050-6. View

16.

Germain R, Margulies D . The biochemistry and cell biology of antigen processing and presentation. Annu Rev Immunol. 1993; 11:403-50. DOI: 10.1146/annurev.iy.11.040193.002155. View

17.

Yamaguchi T, Sakaguchi S . Regulatory T cells in immune surveillance and treatment of cancer. Semin Cancer Biol. 2005; 16(2):115-23. DOI: 10.1016/j.semcancer.2005.11.005. View

18.

Giatromanolaki A, Bates G, Koukourakis M, Sivridis E, Gatter K, Harris A . The presence of tumor-infiltrating FOXP3+ lymphocytes correlates with intratumoral angiogenesis in endometrial cancer. Gynecol Oncol. 2008; 110(2):216-21. DOI: 10.1016/j.ygyno.2008.04.021. View

19.

Han L, Fletcher M, Urbauer D, Mueller P, Landen C, Kamat A . HLA class I antigen processing machinery component expression and intratumoral T-Cell infiltrate as independent prognostic markers in ovarian carcinoma. Clin Cancer Res. 2008; 14(11):3372-9. PMC: 3426216. DOI: 10.1158/1078-0432.CCR-07-4433. View

20.

Jung K, Won Y, Kong H, Oh C, Seo H, Lee J . Cancer statistics in Korea: incidence, mortality, survival and prevalence in 2010. Cancer Res Treat. 2013; 45(1):1-14. PMC: 3629358. DOI: 10.4143/crt.2013.45.1.1. View